Surfactant Administration During Spontaneous Breathing
- Conditions
- PneumothoraxPulmonary Interstitial EmphysemaBronchopulmonary Dysplasia
- Interventions
- Procedure: Take careProcedure: InSurE
- Registration Number
- NCT01329432
- Lead Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
- Brief Summary
Spontaneous breathing supported by nasal continuous positive airway pressure (nCPAP) is thought to have some advantages compared with mechanical ventilation in premature infants. In addition, early surfactant administration has been shown to be superior to delayed use. The aim of this pilot study was to describe the feasibility of TAKE CARE (early administration of surfactant in spontaneous breathing) procedure and compare its short-term and long-term results with InSurE procedure.
- Detailed Description
In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing. In the control group infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration. The procedures were compared for short-term efficacy and possible complications.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- All infants who presented with clinical anl laboratory signs of RDS
- infants who required intubation or PPV right after birth
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description take care Take care In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing InSurE InSurE infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration
- Primary Outcome Measures
Name Time Method nasal cPAP failure and need for mechanical ventilation within 72 hours first 72 hours
- Secondary Outcome Measures
Name Time Method incidence of bronchopulmonary dysplasia 8-10 weeks
Trial Locations
- Locations (1)
Zekai tahir Burak Materntiy Teaching Hospital, Neonatal Intensive Care Unit
🇹🇷Ankara, Turkey